Pfizer's new cancer drug combo tested in tiny early trial

NCT ID NCT06974734

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08046037 (also called SGN-PDL1iT) and sasanlimab
What this could lead to: If it works, this could point toward a new treatment option for certain advanced cancers that have stopped responding to other therapies.
What could go wrong: This was a very early Phase 1 trial with only 8 participants, and it was terminated early. It is too small and preliminary to know if the drug is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma pancreatic ductal adenocarcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG CARCINOMA, PANCREATIC DUCTAL MALIGNANT MELANOMA SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Contacts and locations

Locations

Community Health Network, Inc

Indianapolis, Indiana, 46219, United States
Community Health Network, Inc.

Indianapolis, Indiana, 46227, United States
Community Health Network, Inc.

Indianapolis, Indiana, 46250, United States
Community Health Network, Inc.

Indianapolis, Indiana, 46256, United States
Pan American Center for Oncology Trials, LLC

Rio Piedras, 00935, Puerto Rico
Presbyterian/ St. Lukes Medical Center

Denver, Colorado, 80218, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute - Pharmacy

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States
Smilow Cancer Hospital - Trumbull

Trumbull, Connecticut, 06611, United States
Smilow Cancer Hospital - Yale New Haven Health

New Haven, Connecticut, 06510, United States
Smilow Cancer Hospital Phase 1 Unit

New Haven, Connecticut, 06511, United States
Tristar Centennial Medical Center

Nashville, Tennessee, 37203, United States
Yale - New Haven Hospital - Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.